Clinical trial NCT03032510: Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
Official title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Complicated Urinary Tract Infections
Lead sponsor: La Jolla Pharmaceutical Company
Sponsor class: INDUSTRY
First posted: 2017-01-26
Enrollment: 1205
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of eravacycline compared to ertapenem in treating participants with complicated urinary tract infections (cUTI).

Detailed description: The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of eravacycline compared to ertapenem in treating participants with complicated urinary tract infections (cUTI).

This is a phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety and pharmacokinetics of eravacycline compared with ertapenem in the treatment of cUTI.

Randomization will be stratified based on two criteria: (1) by primary site of infection (pyelonephritis and normal urinary tract anatomy vs all other diagnoses) and (2) by the receipt of a single dose of effective non-study antibiotics for the acute cUTI within 72 hours prior to randomization. An enrollment cap of approximately 50% is planned for subjects with pyelonephritis with normal urinary tract anatomy. Also, an enrollment cap of approximately 20% is planned for subjects who have received a single dose of non-study antibiotics for the acute cUTI within 72 hours prior to randomization.

In this study subjects will be enrolled and randomized to one of two treatment arms in a 1:1 ratio: (i) eravacycline intravenously (IV) / levofloxacin (PO), or (ii) ertapenem (IV) / levofloxacin (PO).

Eligibility criteria: Inclusion Criteria:

1. Male or female participant with either:

   1. Pyelonephritis and normal urinary tract anatomy (approximately 50% of the total population), or
   2. cUTI with at least one of the following conditions associated with a risk for developing cUTI:

      * Indwelling urinary catheter
      * Urinary retention (at least approximately 100 milliliters (mL) of residual urine after voiding)
      * History of neurogenic bladder
      * Partial obstructive uropathy (for example, nephrolithiasis, bladder stones, and ureteral strictures)
      * Azotemia of renal origin (not congestive heart failure \[CHF\] or volume related) such that the serum blood urea nitrogen \[BUN\] is elevated (\>20 milligrams \[mg\]/deciliters \[dL\]) and the serum BUN:creatinine ratio is \<15
      * Surgically modified or abnormal urinary tract anatomy (for example, bladder diverticula, redundant urine collection system) except urinary tract surgery within the last 30 days (placing of stents or catheters is not considered to be surgical modification)
2. At least 18 years of age at time of consent
3. Able to provide informed consent
4. At least two of the following signs or symptoms:

   1. Chills, rigors, or warmth associated with fever or hypothermia
   2. Flank pain (pyelonephritis) or pelvic pain (cUTI)
   3. Nausea or vomiting
   4. Dysuria, urinary frequency, or urinary urgency
   5. Costo-vertebral angle tenderness on physical examination
5. Urine specimen with evidence of pyuria

   1. Dipstick analysis positive for leukocyte esterase (where positive result is at least "++" as indicated on the urine dipstick provided in the laboratory kit), or
   2. ≥10 white blood cells (WBCs) per cubic millimeter, or
   3. ≥10 WBCs per high power field
6. If male: must agree to use an effective barrier method of contraception (for example, condom) during the study and for 14 days following the last dose if sexually active with a female of childbearing potential
7. If female, not pregnant or nursing or, if of childbearing potential: must commit to either use at least two medically accepted, effective methods of birth control (for example, condom, spermicidal gel, oral contraceptive, indwelling intrauterine device, hormonal implant /patch, injections, approved cervical ring) during study drug dosing and for 14 days following last study drug dose or practicing sexual abstinence

Exclusion Criteria:

1. Use of systemic antibiotics effective in cUTI within 72 hours prior to enrollment except under the following circumstances:

   1. Participants with suspected acute cUTI who have received a single dose of effective non-study antibiotics for the acute cUTI
   2. Signs and symptoms of cUTI developed while on the antibiotic for another indication
2. History of an ertapenem-resistant urinary tract infection within 1 year of enrollment
3. Likely to require \>10 days of antibiotic treatment to cure the acute cUTI or likely to receive ongoing antibacterial drug prophylaxis prior to the Follow Up visit (21-28 days after randomization) \[for example, participants with chronic vesiculo-ureteral reflux\]
4. Unlikely to survive at least through the duration of the study
5. Hypotension, systolic blood pressure ≤90 millimeters of mercury \[mmHg\]
6. Complicated pyelonephritis with complete obstruction or known or suspected renal or perinephric abscess, emphysematous pyelonephritis, or Any condition likely to require surgery to achieve cure (this does not include procedure to place catheters or obtain diagnosis)
7. Known or suspected urinary fungal infection
8. Uncomplicated lower urinary tract infections
9. Suspected or confirmed active prostatitis, or currently under treatment for prostatitis
10. High risk for cUTI due to Pseudomonas (for example, history of prior cUTIs due to Pseudomonas, ≥20 mg once a day prednisone or equivalent steroid, and other risk factors as perceived by the Investigator)
11. History of renal transplantation
12. Presence of an ileal loop
13. Any history of trauma to the pelvis or urinary tract occurring within 30 days of screening
14. Indwelling urinary catheters present at screening which are not expected to be removed or replaced within 72 hours of enrollment (for example, nephrostomy tubes, stents, urethral and suprapubic catheters).
15. Known concomitant human immunodeficiency virus (HIV) infection with CD4 counts below 200 within the last six months, or an acquired immune deficiency syndrome (AIDS) defining diagnosis within the last six months
16. Neutropenia (Absolute neutrophil count \<1,000 polymorphonuclear leukocytes \[PMNs\]/microliters \[µL\])
17. Participation in a study with an experimental drug or device within 30 days prior to enrollment
18. Known or suspected hypersensitivity to tetracyclines, carbapenems, or β-lactams
19. History of seizures
20. Any other unstable or clinically significant concurrent medical condition (for example, immunosuppressive therapy, chemotherapy, class IV heart or lung disease, end stage renal disease, or requiring hemodialysis) that would, in the opinion of the Investigator, jeopardize the safety of a participant and/or their compliance with the protocol

Primary outcomes:
measure: Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the EOI Visit
timeFrame: End of Infusion
measure: Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the Test-Of-Cure (TOC) Visit
timeFrame: TOC visit (14-17 days after randomization)
Secondary outcomes:
measure: Proportion of Participants in the ITT Population With Favorable Clinical Outcomes at TOC Visit
timeFrame: TOC visit (14-17 days after randomization)
Other outcomes:
Locations:
city: Fullerton
country: United States
state: California
city: Los Angeles
country: United States
state: California
city: Torrance
country: United States
state: California
city: Coral Gables
country: United States
state: Florida
city: Doral
country: United States
state: Florida
city: Miami
country: United States
state: Florida
city: Columbus
country: United States
state: Georgia
city: Saint Louis
country: United States
state: Missouri
city: Las Vegas
country: United States
state: Nevada
city: Baytown
country: United States
state: Texas
city: Graz
country: Austria
city: Linz
country: Austria
city: Salzburg
country: Austria
city: Pleven
country: Bulgaria
city: Plovdiv
country: Bulgaria
city: Razgrad
country: Bulgaria
city: Ruse
country: Bulgaria
city: Smyadovo
country: Bulgaria
city: Sofia
country: Bulgaria
city: Varna
country: Bulgaria
city: Veliko Tarnovo
country: Bulgaria
city: Tallinn
country: Estonia
city: Tartu
country: Estonia
city: Voru
country: Estonia
city: K'ut'aisi
country: Georgia
city: T'bilisi
country: Georgia
city: Baja
country: Hungary
city: Budapest
country: Hungary
city: Miskolc
country: Hungary
city: Nagykanizsa
country: Hungary
city: Nyiregyhaza
country: Hungary
city: Sopron
country: Hungary
city: Szentes
country: Hungary
city: Tatabanya
country: Hungary
city: Jelgava
country: Latvia
city: Riga
country: Latvia
city: Valmiera
country: Latvia
city: Chisinau
country: Moldova, Republic of
city: Braşov
country: Romania
city: Bucharest
country: Romania
city: Craiova
country: Romania
city: Oradea
country: Romania
city: Arkhangel'sk
country: Russian Federation
city: Moscow
country: Russian Federation
city: Pyatigorsk
country: Russian Federation
city: Rostov-on-the-Don
country: Russian Federation
city: Saint Petersburg
country: Russian Federation
city: Smolensk
country: Russian Federation
city: Vsevolozhsk
country: Russian Federation
city: Yaroslavl'
country: Russian Federation
city: Nitra
country: Slovakia
city: Poprad
country: Slovakia
city: Presov
country: Slovakia
city: Svidnik
country: Slovakia
city: Zilina
country: Slovakia
city: Chernihiv
country: Ukraine
city: Chernivtsi
country: Ukraine
city: Dnipro
country: Ukraine
city: Ivano-Frankivsk
country: Ukraine
city: Kharkiv
country: Ukraine
city: Kyiv
country: Ukraine
city: L'viv
country: Ukraine
city: Lviv
country: Ukraine
city: Mykolaiv
country: Ukraine
city: Odesa
country: Ukraine
city: Poltava
country: Ukraine
city: Uzhgorod
country: Ukraine
city: Uzhorod
country: Ukraine
city: Vinnytsya
country: Ukraine
city: Zaporizhia
country: Ukraine
city: Zhytomyr
country: Ukraine
Study officials:
affiliation: Tetraphase Pharmaceuticals
name: Chief Medical Officer
role: STUDY_DIRECTOR
References: